The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

investors.com/news/technology/sarepta-stock-earnings-q1-2025/?src=A00220

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical Food and Drug Administration appointment.
In morning trades on today's stock market, shares of Sarepta Therapeutics (SRPT) tumbled more than 15% to 39.50. That followed a…

This story appeared on investors.com, 2025-05-07 14:14:47.
The Entire Business World on a Single Page. Free to Use →